Current Issues of Pharmacy and Medical Sciences

Gelatinase activities and TIMP-2 serum level in alcohol cirrhosis and chronic pancreatitis

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 1, Pages 57-60

AGNIESZKA MĄDRO1, JOANNA KURZEPA2, GRAŻYNA CZECHOWSKA1,
MARIA SŁOMKA1, KRZYSZTOF CELIŃSKI1, JACEK KURZEPA3

1 Department of Gastroenterology with Endoscopic Unit, Medical University of Lublin, Poland
2 Department of Radiology and Nuclear Medicine, University Hospital No. 4, Lublin, Poland
3 Department of Biochemistry and Molecular Biology, Medical University of Lublin, Poland

DOI: 10.12923/j.2084-980X/26.1/a.12

 

Abstract

There are some divergent data concerning the role of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of MMP (TIMP)-2 in the pathogenesis of alcoholic cirrhosis (AC) and chronic pancreatitis (CP). Our objective was to evaluate the activity of MMP-2, MMP-9 and TIMP-2 serum levels in patients with AC and CP. Twenty-one patients with diagnosis of AC and twenty-two with CP admitted to the outpatient clinic for a control visit were enrolled. All results were compared with age and sex-matched control group (n=19). The sera obtained from venous blood were stored at -70°C for further analysis. Activity of MMP-2 and MMP-9 were evaluated with gelatin zymography, TIMP-2 serum level was analyzed with the usage of ELISA method. A significant decrease of serum MMP-2 activity was noted in sera of AC and CP patients in comparison with control. Activity of MMP-9 was elevated only in CP patients and TIMP-2 serum level was elevated only in AC patients. Decreased activity of MMP-2 in AC patients can contribute to cirrhosis development. The high level of MMP-9 in serum related to CP patients theoretically can exacerbate the inflammatory process within the pancreas.

Keywords

alcoholic cirrhosis, chronic pancreatitis, MMP-2, MMP-9, TIMP-2, zymography

References

  1. Akhmedov V.A., Budylgin A.V., Dolgikh V.T. The matrix metalloproteinase 9 (MMP-9) and TIMP-1 activities in patients with chronic and recurrent pancreatitis. Eksp Klin Gastroenterol., 6, 11, 2010.
  2. Bruno C.M. et al. Altered pattern of circulating matrix metalloproteinases -2, -9 and tissue inhibitor of metalloproteinase -2 in patient with HCV-related chronic hepatitis. Relationship to histological features. Panminerva. Med., 51, 191, 2009.
  3. Chen P. et al. Serum matrix metalloproteinase 9 as a marker for the assessment of severe acute pancreatitis. Tohoku. J. Exp. Med., 208, 261, 2006.
  4. Child C.G., Turcotte J.G. Surgery and portal hypertension. In: The liver and portal hypertension. 1964, Edited by CG Child. pp:50-64. Saunders, Philadelphia.
  5. Consolo M. et al. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int. J. Molecular Med., 24, 143, 2009.
  6. DeClerck Y.A. et al. Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J. Biol. Chem., 266, 3893, 1991.
  7. Descamps F.J. et al. In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J. Pathol., 204, 555, 2004.
  8. Dufour D.R. Assessment of liver fibrosis: can serum become the sample of choice? Clin. Chem., 51, 1763, 2005.
  9. El-Gindy I. et al. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis with HCV related chronic liver disease. Egypt. J. Immunol., 10, 27, 2003.
  10. Fic P., Zakrocka I., Kurzepa J. et al. Matrix metalloproteinases and atherosclerosis. Postepy Hig. Med. Dosw. (Online), 65, 16, 2011.
  11. Gostiljac D. et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome. Acta Physiol. Hung., 98, 91, 2011.
  12. Guo J., Xue P., Yang X.N. Serum Matrix Metalloproteinase-9 is an Early Marker of Pancreatic Necrosis in Patients with Severe Acute Pancreatitis. Hepatogastroenterology, 117, 1594, 2012.
  13. Ishihara T. et al. Immunohistochemical study of transforming growth factor-beta 1, matrix metalloproteinase-2,9, tissue inhibitors of metalloproteinase-1,2, and basement membrane components at pancreatic ducts in chronic pancreatitis. Pancreas, 17, 412, 1998.
  14. Kim J.Y et al. Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med J., 50, 68, 2009.
  15. Krizkova S. et al. Clinical importance of matrix metalloproteinases. Bratisl. Lek. Listy, 112, 435, 2011.
  16. Kurzepa J., Stryjecka-Zimmer M. The effect of interferon β-1a on MMP-2 and MMP-9 proteolytic activity. Folia Biol. (Praha), 53, 220, 2007.
  17. Li L. et al. PSP/Reg inhibits cultured pancreatic stellate cell and regulates MMP/ TIMP ratio. Eur. J. Clin. Invest., 41, 151, 2011.
  18. Lichtinghagen R. et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond). 105, 373, 2003.
  19. Lichtinghagen R. et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin. Chem., 46, 183, 2000.
  20. Lichtinghagen R. al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J. Hepatol., 34, 239, 2001.
  21. Lucivero V. et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol. Sci. 28, 165, 2007.
  22. Madro A. et al. The decrease of serum MMP-2 activity corresponds to alcoholic cirrhosis stage. Alcohol, 46, 155, 2012.
  23. Moore C.S., Crocker S.J. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am. J. Pathol., 180, 12, 2012.
  24. Naveau S. et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49, 97, 2009.
  25. Ng E.K. et al. Decreased type IV collagenase activity in experimental pancreatic fibrosis. J. Surg. Res., 96, 6, 2001.
  26. Onozuka I. et al. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem. Biophys. Res. Commun., 406, 134, 2011.
  27. Opdenakker G., Van den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol., 22, 571, 2001.
  28. Ponomarenko Y. et al. Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol., 37, 252, 2002.
  29. Pugh R.N. et al. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Sur., 60, 646, 1973.
  30. Rydzewska G., Jedynak M. The pathogenesis of alcoholic chronic pancreatitis. Gastroenterol. Pol., 5, 83, 1998.
  31. Yong V.W. et al. Matrix metalloproteinases and diseases of the CNS Trends Neurosci., 21, 75, 1998.
prev next

 

Calendar

July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31